Skip to Content
Merck
HomeWebinarsUnlocking the Potential of Lipid-Based Formulations for mRNA Drug Delivery

Unlocking the Potential of Lipid-Based Formulations for mRNA Drug Delivery



WEBINAR

Topic 1: Lipids Chemistry & NanoFabTx™ Formulations for mRNA Delivery

With recent advances in mRNA vaccines, the demand for drug delivery formulations, specifically in the area of liquid nanoparticle (LNP) formulations, has greatly expanded to overcome many limitations associated with free therapeutics. This webinar will provide an overview of chemistry products for mRNA delivery such as lipid-based formulations, and the various approaches that can be used to fabricate lipid nanoparticles. The solutions available for customers doing research in the area of drug development & delivery will also be covered. 

In this topic, you will learn:

  • Lipids for Drug Delivery
  • Lipid Nanoparticle Fabrication Solutions
  • Other Drug Delivery Solutions

Topic 2: Mastering Lipid Nanoparticle formulation development

Subsequent to the COVID-19 pandemic, advances continue to be made in nucleic acid-based vaccines and therapeutics as researchers explore new formulations for a wider range of applications.

Gain valuable insights into our specialized expertise in developing customized lipid nanoparticle (LNP) formulations for innovative therapeutic methods. This webinar will also showcase our extensive capabilities in Contract Development and Manufacturing Organization (CDMO). 

In this topic, you will learn:

  • How to overcome obstacles in lipid nanoparticle formulation development
  • Key considerations for the process and analytical development of lipid nanoparticles
  • Real-world examples of data showcasing customized lipid nanoparticle formulations, ready for a seamless transition into clinical and commercial drug product development

Speakers

Elizabeth Aisenbrey

Elizabeth Aisenbrey

Merck

Global Product Manager - Biomedical Materials, Materials Science

Elizabeth Aisenbrey is the Global Product Manager for Biomedical Materials in Materials Science. She is responsible for developing and managing the Biomedical Materials portfolio to drive innovation and cultivate new technologies in research areas such as biomedical polymers, drug delivery, tissue engineering and 3D bioprinting. Elizabeth has a PhD in chemical engineering and over ten years of experience in biomedical materials research focused on tissue engineering and in vitro disease modeling.

Kyle Sjoholm

Kyle Sjoholm

Merck

Global Product Manager - Lipids and Avanti, Biochemistry

Kyle Sjoholm is the Global Product Manager for Lipids and Avanti Polar Lipids in Biochemistry. He is responsible for develeoping the lipid portfolio for drug delivery and lipidomics research. Kyle has a M.S. (R) in Analytical Chemistry specializing in drug delivery and electrochemical sensors and years of interdisciplinary research in the chemical industry.

Johanna Simon, Ph.D.

Johanna Simon, Ph.D.

Merck

Principial Scientist

Johanna Simon, Ph.D., is a principal scientist in the Early Formulation Screening Service in Life Science Services at Merck. Her work focuses on the preclinical formulation development of custom lipid nanoparticles for nucleic acid modalities.

After receiving her Ph.D. in Chemistry, Johanna has continued her scientific career as a postdoctoral researcher with a focus on developing antibody-functionalized nanoparticles for targeted drug delivery in vivo. Johanna has authored 50+ peer-reviewed articles in leading journals in the field of drug delivery sciences.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?